Sutro Logo high res
  • Who We Are
    • About Sutro
    • Leadership
      • Leadership Team
      • Board of Directors
      • Scientific Advisory Board
      • Clinical Advisory Board
    • Collaborations
  • Proprietary Platform
  • Pipeline
    • Overview
    • Scientific Publications
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Financials
    • Stock Data
    • Governance
    • IR Resources
  • Careers
    • The Way We Work
    • DEIB
    • Sustainability
    • Internships
    • Philanthropy
      • Employee Engagement
  • Contact Us

Sutro Biopharma Announces Additional Data for Dose-Escalation Phase 1 Study of STRO-002 to be Presented at ASCO 2021

Events, News, Presentations, Press Releases

Sutro Biopharma Announces Additional Data for Dose-Escalation Phase 1 Study of STRO-002 to be Presented at ASCO 2021 Maturing data from the Phase 1 dose-escalation cohort for STRO-002 showed a median progression-free survival of 7.2 months One patient achieved a CR...

Sutro Biopharma to Participate in Upcoming Virtual Investor Conferences

Events, News, Presentations, Press Releases

Sutro Biopharma to Participate in Upcoming Virtual Investor Conferences SOUTH SAN FRANCISCO, Calif., May 14, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise...

Sutro Biopharma Reports First Quarter 2021 Financial Results, Business Highlights and 2021 Anticipated Milestones

News, Press Releases

Sutro Biopharma Reports First Quarter 2021 Financial Results, Business Highlights and 2021 Anticipated Milestones – Additional follow-up data on STRO-002 from the Phase 1 dose-escalation will be presented at ASCO 2021; enrollment for the dose-expansion is...

Sutro Biopharma Promotes Trevor Hallam, Ph.D., to President of Research and Chief Scientific Officer

News, Press Releases

Sutro Biopharma Promotes Trevor Hallam, Ph.D., to President of Research and Chief Scientific Officer SOUTH SAN FRANCISCO, Calif., April 20, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on...

Sutro Biopharma Earns Milestone Payment from Cytokine Derivatives Collaboration with Merck

News, Press Releases

Sutro Biopharma Earns Milestone Payment from Cytokine Derivatives Collaboration with Merck – Initiation of an IND enabling toxicology study for the first program under the 2018 collaboration oncytokine derivatives earns a $15 million milestone payment from Merck...

Sutro Biopharma to Present at Two Upcoming Investor Conferences

Events, News, Presentations, Press Releases

Sutro Biopharma to Present at Two Upcoming Investor Conferences SOUTH SAN FRANCISCO, Calif., April 8, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein...
« Older Entries
Next Entries »

Sutro Biopharma

111 Oyster Point Blvd
South San Francisco, CA 94080

Phone: 650-881-6500

Dedicated to patients
and changing the future of oncology

  • Follow
  • Follow
  • Follow
  • Follow

Follow us on social media

© 2026 Sutro Biopharma, Inc.
South San Francisco, California, U.S.A.

SITE MAP | PRIVACY POLICY  | EMAIL ALERTS | CONTACT US | VISITOR GUIDE

 

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in .

Sutro Biopharma, Inc.
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.